AlphAIAlphAI — Financial news for AI agents
investing.comNOV 22 min read$WST

Jefferies raises West Pharmaceutical stock price target on HVP growth

Jefferies raised its price target for West Pharmaceutical Services (WST) to $475 from $410, citing growth in high-value products and GLP-1 components. The stock has surged 50% year-to-date. WST reported Q3 2026 earnings of $2.66 per share on revenue of $874.5 million, beating estimates, and raised its full-year outlook.

Original reporting
investing.com
Published Nov 2, 2026, 10:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 10:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$WST
Bullish
high confidence
Mentioned
$WST
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$WSTBullishMed
01

Why it matters

The new target could attract buying interest, but investors should monitor Q4 guidance for margin pressure.

02

Market read

Analyst upgrade provides a fresh catalyst for WST, potentially influencing sector peers.

03

What to watch

Potential headwinds from GLP-1 revenue slowdown and margin pressure.

Relevance 6/10Novelty 6/10Timing: today

Background

Jefferies' upgrade follows West Pharmaceutical's strong Q3 results and highlights growth in its high-value product segment.

Company-level read

Ticker impact

$WSTBullishHigh confidence
Context

Jefferies raised its price target on West Pharmaceutical Services to $475, citing expanding high-value product opportunities and GLP-1 growth.

Expected impact

likely upward pressure as investors price in the new target

Evidence & confidence

The upgrade is fresh and includes a specific price target, providing a clear catalyst for buying interest.

Market effects

Sector

Positive outlook for high-value pharmaceutical components may lift peers in the injectable drug packaging sector.

Regional

U.S. pharma stocks could see modest gains.

Global

Limited to investors focused on U.S. healthcare equities.

Counterpoint

What could challenge this read

The target may be overly optimistic given the upcoming Q4 revenue decline.

Key entities

  • Company
    West Pharmaceutical Services

    U.S.-listed provider of injectable drug packaging and delivery solutions.

  • Research Firm
    Jefferies

    Investment bank that issued the upgraded price target.

Read at source← All news

Related articles

OCT 31
$WSTHighAI 8/10

What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call

West Pharmaceutical Services reported Q3 revenue of $874M, up 8.7%, with adjusted EPS increasing 36% to $2.66. Strong demand for biologics and GLP-1 therapies drove growth, particularly in proprietary products. The company raised its 2026 outlook, forecasting revenue of $3.41B-$3.42B and adjusted EPS of $9.38-$9.48. West is also expanding HVP capacity and maintaining dividend and share repurchase programs.

finance.yahoo.com2 min
OCT 29
$WSTMed

West Pharmaceutical Services, Inc. Q3 2026 Earnings Call Summary

West Pharmaceutical Services reported Q3 2026 earnings, highlighting 16.6% growth in proprietary products, driven by HVP components and GLP-1 treatments. Gross margins expanded by 310 basis points due to a shift toward high-value products. The company raised full-year organic growth guidance to 11.3%-11.6% and announced an 18% dividend increase. Management discussed strategic shifts, including divestitures and capital investments in HVP capacity.

finance.yahoo.com6 min
OCT 29
$WSTMedAI 8/10

West Pharmaceutical Services Inc (WST) (Q3 2026) Earnings Call Highlights: Record Margins

West Pharmaceutical Services reported Q3 2026 earnings with record margins, but faced revenue declines in the West Vantage segment and a planned divestiture headwind. Free cash flow decreased 5% year-over-year. CEO Michel Lagarde emphasized strong organic growth prospects and high M&A criteria. GLP-1 revenue growth is expected to decelerate due to tough comparisons. The company anticipates continued margin expansion and plans to invest in high-return HVP areas.

finance.yahoo.com3 min